ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET

Company Participants

Jessica Tieszen - Associate Director of Investor Relations

Albert Kildani - Senior Vice President, Investor Relations & Corporate Communications

Steve Davis - Chief Executive Officer

Brendan Teehan - Chief Operating Officer, Head of Commercial

Doug Williamson - Head of Research & Development

Mark Schneyer - Chief Financial Officer

Parag Meswani - Senior Vice President: Trofinetide, Rare Diseases Franchise

Kathie Bishop - Head of Rare Diseases & External Innovation

Conference Call Participants

Ritu Baral - TD Cowen

Tessa Romero - J.P. Morgan

Yatin Suneja – Guggenheim

Jeff Hung - Morgan Stanley

Charles Duncan - Cantor Fitzgerald

Ash Verma - UBS

Tazeen Ahmad - Bank of America

Sumant Kulkarni - Canaccord Genuity

Ami Fadia - Needham & Company

Jay Olson - Oppenheimer

Operator

Good day ladies and gentlemen and welcome to ACADIA Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. My name is Kathy and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call.

I would now like to turn the presentation over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please proceed.

Albert Kildani

Thank you, Kathy. Good afternoon and thank you for joining us on today's call to discuss ACADIA’s third quarter 2023 earnings. Joining me on the call today from ACADIA are Steve Davis, our President and Chief Executive Officer, who will provide some opening remarks followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial, who will discuss the DAYBUE launch and NUPLAZID execution. Doug Williamson, our Head of Research and Development will provide an update on our pipeline programs; and Mark Schneyer, our Chief Financial Officer will review the financial results. Steve will then provide some closing thoughts before we open the call up for your questions.

In addition, both Kathie Bishop, our Head of Rare Diseases and External Innovation, and Parag Meswani, Senior Vice President: Trofinetide, Rare Diseases Franchise, will be available for the Q&A session. We are using supplemental slides which are available on the website's Events and Presentations section.

Before proceeding, I would like to remind you that during our call today we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements including goals, expectations, plans, prospects, growth potential, timing of events or future results are based on current information, assumptions, and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements which are made only as of today's date.